Currently, there are three major DOACs available—Factor Xa inhibitors (apixaban and rivaroxaban) and direct thrombin inhibitors (dabigatran)—that are available for use in atrial fibrillation and venous thromboembolism. The gene discussed is F10; the disease is venous thromboembolism.